Safety, Tolerability, and Pharmacodynamic Effect Study of PUR118

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01333904
Recruitment Status : Completed
First Posted : April 12, 2011
Last Update Posted : September 7, 2012
Quotient Bioresearch
Information provided by (Responsible Party):
Pulmatrix Inc.

Brief Summary:
The purpose of this study is to establish single and multiple dose safety in healthy subjects and subjects with mild chronic pulmonary obstructive disease (COPD). In addition, the study will evaluate preliminary proof of concept endpoints in COPD subjects such as biomarkers in sputum and mucociliary clearance.

Condition or disease Intervention/treatment Phase
Chronic Obstructive Pulmonary Disease Drug: PUR118 Phase 1

Detailed Description:
The proposed initial trial in healthy subjects and subjects with mild COPD will establish the tolerability of PUR118 in these subjects over single and short multi-day dosing periods. The study will also provide preliminary data regarding PUR118's potential impact on biomarkers in COPD. Finally, this trial will assess PUR118's effect on mucociliary clearance. This is a four part study enrolling healthy volunteers in a single ascending dose design (SAD; Part I), followed by multiple ascending dose design (MAD; Part II). Contingent on demonstration of safety in a healthy subject population, the study will enroll mild COPD subjects for a short multi-dose design (Part III) incorporating safety and pharmacodynamic endpoints. Lastly Part IV of the trial will assess the effect of PUR118 on mucociliary clearance in mild COPD subjects.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Four-Part Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of PUR118 and Placebo in Normal Healthy Volunteers and Subjects With COPD
Study Start Date : February 2011
Actual Primary Completion Date : June 2012
Actual Study Completion Date : June 2012

Arm Intervention/treatment
Experimental: PUR118 Drug: PUR118

Primary Outcome Measures :
  1. Safety and tolerability assessed by changes in clinical signs and symptoms, clinical safety laboratory tests, vital signs, ECG, spirometry, oxygen saturation, telemetry and adverse events [ Time Frame: 2 weeks ]

Secondary Outcome Measures :
  1. Assessment of biomarkers of inflammation and COPD in induced sputum in mild COPD subjects after short multi-dosing with PUR118 compared to baseline [ Time Frame: 2 days ]
  2. Assessment of changes in mucociliary clearance after treatment with PUR118 in mild COPD subjects compared to baseline [ Time Frame: single dose ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Main Inclusion Criteria Parts I & II

  • Healthy males or non pregnant, non lactating healthy females;
  • Age 18-65 years of age;
  • Must be willing and able to communicate in English and participate in the whole study;
  • Must provide written informed consent.

Main Exclusion Criteria Parts I & II

  • Current smokers and those who have smoked within the last 12 months;
  • Females of child bearing age not willing to use an acceptable form of contraception;
  • Presence or history of allergy requiring treatment;
  • Serious adverse reaction or hypersensitivity to any drug;

Main Inclusion Criteria: Parts III and IV

  • Males or non pregnant, non lactating females;
  • Age 45-70 years;
  • Current (Part III only) or ex-smokers who at least a 15 pack-year smoking history. For Part IV, subjects must be non-smokers for at least 3 months;
  • Medically stable, with no evidence of uncontrolled co-existing conditions at screening;
  • Must not be taking any inhaled or oral corticosteroids;
  • FEV1/FVC ratio <70% and FEV1 60 - 80% (or >/= 60% for Part IV only) of predicted following administration of a bronchodilator;
  • Patients must have a medical history of COPD confirmed by their General Practitioner (GP) or treating hospital physician or must have a chest x-ray (CXR) which is normal or consistent with mild COPD and excludes other clinically significant respiratory abnormalities;
  • Must be willing and able to communicate in English and participate in the whole study;
  • Must provide written informed consent.

Main Exclusion Criteria: Parts III and IV

  • Must agree to use an adequate method of contraception;
  • Upper respiratory tract infection within 30 days of the first study day, or lower respiratory tract infection within the last 60 days;
  • Patients taking medication that may affect the respiratory tract within 14 days of the first study day other than their usual COPD medication;
  • No active exacerbations requiring antibiotics or steroids within 60 days of dosing.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01333904

United Kingdom
Quotient Bioresearch
Nottingham, United Kingdom, NG11 6JS
Sponsors and Collaborators
Pulmatrix Inc.
Quotient Bioresearch
Principal Investigator: Stuart Mair, MD Quotient Bioresearch

Responsible Party: Pulmatrix Inc. Identifier: NCT01333904     History of Changes
Other Study ID Numbers: 601-0004
First Posted: April 12, 2011    Key Record Dates
Last Update Posted: September 7, 2012
Last Verified: September 2012

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases